BioCardia Files 8-K: Other Events & Financials
Ticker: BCDA · Form: 8-K · Filed: Nov 24, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Nov 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: BCDA
TL;DR
BioCardia dropped an 8-K on 11/24/25 - check for updates on events and financials.
AI Summary
BioCardia, Inc. filed an 8-K on November 24, 2025, reporting other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is based in Sunnyvale, California, and operates in the biological products sector.
Why It Matters
This filing indicates BioCardia is providing updates on its corporate activities and financial status, which is important for investors to monitor the company's ongoing operations and compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events or financial updates without inherently introducing new risks.
Key Numbers
- 20251124 — Filing Date (Date of the 8-K filing)
- 1231 — Fiscal Year End (Indicates the end of the company's fiscal year)
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- November 24, 2025 (date) — Date of earliest event reported
- Sunnyvale, California (location) — Principal executive offices
- 001-38999 (other) — Commission File Number
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating it is an item reported in the 8-K.
What is the primary business of BioCardia, Inc.?
BioCardia, Inc. is in the business of 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its Standard Industrial Classification code.
When was BioCardia, Inc. previously known by another name?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc., with a name change date of June 16, 2011.
Where are BioCardia, Inc.'s principal executive offices located?
The principal executive offices of BioCardia, Inc. are located at 320 Soquel Way, Sunnyvale, California 94085.
What is the SEC file number for BioCardia, Inc.?
The SEC file number for BioCardia, Inc. is 001-38999.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-11-24 08:00:43
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20251121_8k.htm (8-K) — 27KB
- ex_892143.htm (EX-99.1) — 8KB
- 0001437749-25-036076.txt ( ) — 166KB
- bcda-20251124.xsd (EX-101.SCH) — 3KB
- bcda-20251124_def.xml (EX-101.DEF) — 11KB
- bcda-20251124_lab.xml (EX-101.LAB) — 15KB
- bcda-20251124_pre.xml (EX-101.PRE) — 11KB
- bcda20251121_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 24, 2025, BioCardia, Inc. issued a press release announcing the appointment of Farhan Shahab as Vice President of Quality. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated November 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: November 24, 2025